Mar 7, 2023 | Press Releases
CUPERTINO, Calif., March 07, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Jan 31, 2023 | Press Releases
Cupertino, Calif., Jan. 31, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Jan 4, 2023 | Press Releases
CUPERTINO, Calif., Jan. 04, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Dec 15, 2022 | Press Releases
– Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 – Brilaroxazine is a serotonin/dopamine modulator with a differentiated pharmacological and safety profile CUPERTINO, Calif., Dec. 15, 2022...
Nov 22, 2022 | Press Releases
– Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 – Brilaroxazine is a serotonin/dopamine modulator with a differentiated pharmacological and safety profile CUPERTINO, Calif., Dec. 15, 2022...
Nov 21, 2022 | Press Releases
– RP1208 is in preclinical development for the potential treatment of depression and obesity – – Composition of matter patents for RP1208 have been granted in key markets around the world including the United States, Europe, China, and Japan –...
